Aktiesnakken — November 2009
-
reducerer det ikke vores chancer for at blive godkendt i 1st line, var vores fase 2 ikke sammenlignelige, men kan det være bivirkninger?
-
About 15,490 new cases of CLL will be diagnosed in 2009. It is estimated that 85,710 people in the United States are living with or are in remission from CLL.
-
ja og 250K worldwide
-
du kan jo gange 85K med 44K
-
det er umuligt at Ritux godkendes i 3rd line
-
men det betyder vel reelt at HVIS arzerra godkendes i 1st line så er Ritux ude af CLL
-
bivirkningerne...det er der hunden ligger negravet
-
er det det her arzerra 1.line studie som forventes færdigt i 2013? http://clinicaltrials.gov/ct2/show/NCT00748189?term=arzerra&rank=14
-
men ser selve virkningen ikke god ud for ritux?
-
jeg faldt ned af stolen stinker
-
det her til forventet afslutning medio 2011 http://clinicaltrials.gov/ct2/show/NCT00824265?term=arzerra&rank=19
-
og med den her helt nye kæmpe cll præsentation så formoderr jeg ik jeg høre mere til jer det næste stykke tid
hematology.wustl.edu/conferences/presentations/ansstas100209.ppt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind